Second Affiliated Hospital, School of Medicine, Zhejiang University: Lymphoma trials
The registry lists 19 Lymphoma studies with Second Affiliated Hospital, School of Medicine, Zhejiang University as lead sponsor. 12 are open to participants now and 1 have results posted.
Phase 1 6Phase 2 7Phase 3 1No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- AI-assisted Diagnosis of Malignant Brain TumorsRecruitingNCT07198256
- Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone LymphomaRecruitingNCT07022223Phase 2
- A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
- Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell LymphomaRecruitingNCT06464861Phase 1
- Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPIRecruitingNCT06290817Phase 2
- Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin LymphomaRecruitingNCT05667155Phase 1
- Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT05600660Phase 2
- Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell LymphomaRecruitingNCT05585996Phase 1
- Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHLRecruitingNCT05453669Phase 1
- Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaRecruitingNCT04922567Phase 2
- Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell LymphomaRecruitingNCT04887025Phase 1
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
- 18F-FDG PET Radiomics of Diffuse Large B-cell LymphomaCompletedNCT04317313Results posted
- A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell LymphomaStatus unknownNCT05495100Phase 2
- Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCLCompletedNCT05113576
- the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After ChemotherapyStatus unknownNCT04914143Not applicable
- Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in LymphomaStatus unknownNCT04910594Phase 3
- A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04845139Not applicable
- CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT04381741Phase 1